VerImmune
VerImmune is developing a breakthrough therapy called Anti-Tumor Immune Redirection (AIR) that redirects immune memory against pathogens or childhood vaccines to target cancer. Their strategy involves screening for pre-existing immunity, modifying tumor cells to appear as virally infected, and leveraging immune memory to induce tumor cell death. The company aims to address the growing global burden of cancer, with over 14 million new cases annually and significant expenditure on cancer treatments.
Industries
Nr. of Employees
small (1-50)
Patents
Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
US-12344637-B2
View DetailsChimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US-11944677-B2
View DetailsVirus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
US-11858964-B2
View DetailsConjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US-11560408-B2
View DetailsChimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US-11285203-B2
View Details
Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
US-12344637-B2
View DetailsChimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US-11944677-B2
View DetailsVirus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer
US-11858964-B2
View DetailsConjugated virus-like particles and uses thereof as anti-tumor immune redirectors
US-11560408-B2
View DetailsChimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
US-11285203-B2
View DetailsProducts
Anti-tumor immune redirection therapy (AIR)
A therapeutic approach that redirects pre-existing immune memory from pathogens or childhood vaccines to target cancer by modifying tumor cells to present viral/pathogen-associated antigens, leading to CD8+ T cell-mediated tumor cell death.
Anti-tumor immune redirection therapy (AIR)
A therapeutic approach that redirects pre-existing immune memory from pathogens or childhood vaccines to target cancer by modifying tumor cells to present viral/pathogen-associated antigens, leading to CD8+ T cell-mediated tumor cell death.
Services
Assay-based screening to detect retained immune memory to prior infections or childhood vaccines to inform patient selection for immune-redirection therapy.
Assay-based screening to detect retained immune memory to prior infections or childhood vaccines to inform patient selection for immune-redirection therapy.
Expertise Areas
- Immune memory-based immunotherapy
- Biomarker-driven patient selection
- Tumor antigen engineering
- T cell-mediated cytotoxicity
Key Technologies
- Immune memory redirection
- Tumor antigen engineering (viral antigen mimicry)
- Biomarker assays for prior pathogen/vaccine exposure
- CD8+ T cell activation/redirection